Literature DB >> 12426045

MDMA alters the response of the circadian clock to a photic and non-photic stimulus.

Suzanne Colbron1, Mark Jones, Stephany M Biello.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA or 'Ecstasy') is a widely used recreational drug that damages serotonin 5-HT neurons in animals and possibly humans. Published literature has shown that the serotonergic system is involved in photic and non-photic phase shifting of the circadian clock, which is located in the suprachiasmatic nuclei. Despite the dense innervation of the circadian system by 5-HT and the known selective neurotoxicity of MDMA, little is known about the effects of MDMA on the circadian oscillator. This study investigated whether repeated exposure to the serotonin neurotoxin MDMA alters the behavioural response of the Syrian hamster to phase shift to the serotonin 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). This agonist was administered under an Aschoff Type I (CT8) and Aschoff Type II (ZT8) paradigm (5 mg/kg) and was given before and after treatment with MDMA (10, 15 and 20 mg/kg administered on successive days). Pre-treatment with MDMA significantly attenuated phase shifts to 8-OH-DPAT. We also tested the ability of the clock to phase shift to a photic stimulus after treatment with MDMA. A 15-min light pulse (mean lux 125 at CT14 or ZT14) was administered before and after treatment with MDMA. Phase shifts to a photic stimulus were significantly attenuated by pre-treatment with MDMA. Our study demonstrates that repeated exposure to MDMA may alter the ability of the circadian clock to phase shift to a photic and non-photic stimulus in the hamster. Disruption of circadian function has been linked with a variety of clinical conditions such as sleep disorders, mood, concentration difficulties and depression, consequently outlining the potential dangers of long-term ecstasy use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426045     DOI: 10.1016/s0006-8993(02)03478-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart.

Authors:  Christopher A Koczor; Ivan Ludlow; Robert S Hight; Zhe Jiao; Earl Fields; Tomika Ludaway; Rodney Russ; Rebecca A Torres; William Lewis
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

2.  MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei.

Authors:  Rowan P Ogeil; David J Kennaway; Mark D Salkeld; Shantha M W Rajaratnam; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

3.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

4.  Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users.

Authors:  Mark Blagrove; Jennifer Seddon; Sophie George; Andrew C Parrott; Robert Stickgold; Matthew P Walker; Katy A Jones; Michael J Morgan
Journal:  J Psychopharmacol       Date:  2010-07-08       Impact factor: 4.153

5.  Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night.

Authors:  K P C Kuypers; M Wingen; N Samyn; N Limbert; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.415

6.  Effects of 3,4-methylenedioxymethamphetamine administration on retinal physiology in the rat.

Authors:  João Martins; Miguel Castelo-Branco; Ana Batista; Bárbara Oliveiros; Ana Raquel Santiago; Joana Galvão; Eduarda Fernandes; Félix Carvalho; Cláudia Cavadas; António F Ambrósio
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.